Evidence map›Paper›PMID 39948407›Full record

ArticleNature medicine2025

Author Correction: Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.

Saad Z Usmani, Thierry Facon, Vania Hungria, Nizar J Bahlis, Christopher P Venner, Marc Braunstein, Ludek Pour, Josep M Martí, Supratik Basu, Yael C Cohen and 21 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

31 authors.

Saad Z UsmaniMemorial Sloan Kettering Cancer Center, New York, NY, USA. usmanis@mskcc.org.ORCID http://orcid.org/0000-0002-5484-8731
Thierry FaconUniversity of Lille, CHU de Lille, Service des Maladies du Sang, Lille, France.
Vania HungriaClínica Médica São Germano, São Paulo, Brazil.
Nizar J BahlisArnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Alberta, Canada.ORCID http://orcid.org/0000-0001-7353-7034
Christopher P VennerDepartment of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada.
Marc BraunsteinPerlmutter Cancer Center, NYU Langone Health, New York, NY, USA.
Ludek PourUniversity Hospital Brno, Brno, Czech Republic.
Josep M MartíHospital Universitario Mútua de Terrassa, Terrassa, Spain.
Supratik BasuRoyal Wolverhampton NHS Trust and University of Wolverhampton, CRN West Midlands, National Institute for Health and Care Research, Wolverhampton, UK.ORCID http://orcid.org/0000-0003-2206-4796
Yael C CohenDepartment of Hematology, Tel Aviv Sourasky (Ichilov) Medical Center, Tel Aviv, Israel.ORCID http://orcid.org/0000-0002-9061-7287
Morio MatsumotoDepartment of Hematology, National Hospital Organization Shibukawa Medical Center, Gunma, Japan.
Kenshi SuzukiDepartment of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Cyrille HulinDepartment of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac, France.
Sebastian GrosickiDepartment of Hematology and Cancer Prevention, School of Public Health, Medical University of Silesia, Katowice, Poland.
Wojciech LegiecDepartment of Hematology and Bone Marrow Transplantation, St. John of Dukla Oncology Center of Lublin Land, Lublin, Poland.
Meral BeksacIstinye University, Ankara Liv Hospital, Ankara, Turkey.
Angelo MaiolinoInstituto Americas de Ensino, Pesquisa e Inovação, Rio de Janeiro, Brazil.ORCID http://orcid.org/0000-0003-0140-9548
Hiroyuki TakamatsuDepartment of Hematology, Kanazawa University Hospital, Kanazawa University, Kanazawa, Japan.
Aurore PerrotCHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d'Hématologie, Toulouse, France.ORCID http://orcid.org/0000-0003-0131-8689
Mehmet TurgutDepartment of Hematology, Ondokuz Mayıs University Faculty of Medicine, Samsun, Turkey.
Tahamtan AhmadiGenmab US, Inc., Plainsboro, NJ, USA.
Weiping LiuJohnson & Johnson, Shanghai, China.
Jianping WangJohnson & Johnson, Spring House, PA, USA.
Katherine ChastainJohnson & Johnson, Raritan, NJ, USA.
Jessica VermeulenJohnson & Johnson, Leiden, The Netherlands.
Maria KrevvataJohnson & Johnson, Spring House, PA, USA.
Lorena Lopez-MasiJohnson & Johnson, Raritan, NJ, USA.
Jodi CareyJohnson & Johnson, Spring House, PA, USA.
Melissa RoweJohnson & Johnson, High Wycombe, UK.
Robin CarsonJohnson & Johnson, Spring House, PA, USA.
Sonja ZweegmanDepartment of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39948407
PMCPMC12003187

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.